Topiramate is not classified as a mood stabilizer, despite being prescribed alongside them and sometimes mistaken for one. It is an anticonvulsant, originally approved for epilepsy and later for migraine prevention, that has accumulated a long list of off-label psychiatric uses. The confusion is understandable: several established mood stabilizers, like valproate and lamotrigine, are also anticonvulsants, and topiramate does turn up in the treatment plans of people with bipolar disorder. But when researchers have tested whether topiramate actually stabilizes mood on its own, the results have been disappointing in ways that matter.
How Topiramate Works in the Brain
Topiramate has an unusually broad set of actions in the nervous system, which partly explains why it keeps showing up in so many different clinical contexts. It boosts the activity of GABA, the brain’s main inhibitory signaling molecule, at one of its key receptors. It also dials down excitatory signaling by blocking certain sodium channels and inhibiting a type of glutamate receptor. On top of that, it inhibits carbonic anhydrase, an enzyme involved in fluid and acid-base balance throughout the body.1PubMed. Concentration-effect studies with topiramate on selected enzymes and intermediates of the GABA shunt This cocktail of mechanisms is part of what makes topiramate useful for seizures and migraines, and it is also why researchers have explored it for mood, addiction, binge eating, and impulsivity. The drug was actually discovered by accident during a search for a new diabetes medication.2PubMed. Sugar sulfamates for seizure control: discovery and development of topiramate, a structurally unique antiepileptic drug
Why People Confuse It With a Mood Stabilizer
The “mood stabilizer” label gets applied loosely in everyday conversation, but in psychiatry it has a more specific meaning. A true mood stabilizer treats or prevents both the highs (mania) and the lows (depression) of bipolar disorder without making either pole worse. Lithium is the classic example. Valproate and lamotrigine, both anticonvulsants, also qualify because they have strong evidence on at least one pole and do not destabilize the other. A 2023 review of first- and second-generation mood stabilizers noted that several anticonvulsants, topiramate among them, show “some usefulness” in bipolar disorder but do not fully meet the criteria to be called mood stabilizers.3PubMed Central. Mood Stabilizers of First and Second Generation
The confusion comes from the fact that topiramate is frequently prescribed as an add-on to mood stabilizers, especially when weight gain or impulsivity are problems. Patients see it listed alongside lithium or valproate in their medication regimen and reasonably assume it belongs to the same category. Clinicians sometimes contribute to the confusion by loosely describing any drug used in bipolar disorder as a “mood stabilizer,” even when it is being prescribed for a secondary purpose like weight management or anxiety reduction.
Topiramate Failed as a Treatment for Mania
The strongest evidence against calling topiramate a mood stabilizer comes from a set of four large, well-designed trials that tested it as a standalone treatment for acute mania. In all four studies, topiramate performed no better than placebo at reducing manic symptoms. Meanwhile, lithium, which was included as an active comparison, showed clear superiority over both placebo and topiramate.4PubMed. Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials The pattern held up through 12 weeks of treatment in studies that had extended follow-up. These results effectively closed the door on topiramate monotherapy for mania, and it is why no major treatment guideline recommends topiramate on its own for bipolar disorder.
A small pilot trial in children and adolescents with bipolar I disorder showed a somewhat more favorable trajectory for topiramate on mania rating scales over the course of the study, but the trial was small and the main pre-specified analyses did not reach statistical significance in a straightforward way. Side effects included decreased appetite, nausea, diarrhea, and tingling sensations.5ScienceDirect (Journal of the American Academy of Child & Adolescent Psychiatry). A Pilot Controlled Trial of Topiramate for Mania in Children and Adolescents With Bipolar Disorder This is thin evidence, and the pediatric data have not changed the overall conclusion from adult trials.
Where Topiramate May Actually Help in Bipolar Disorder
Even though topiramate cannot stand on its own as a mood stabilizer, it has shown promise as an add-on treatment, particularly for bipolar depression and for long-term maintenance. In one small randomized study, topiramate added to a mood stabilizer performed comparably to bupropion (a standard antidepressant used in bipolar depression) at reducing depressive symptoms, with both groups showing meaningful improvement over eight weeks. An earlier open-label trial of 45 patients with treatment-resistant bipolar depression found that most who completed the trial had substantial reductions in depression scores after adding topiramate to their existing regimen.6Neuropsychiatric Disease and Treatment. Psychopharmacology of topiramate: from epilepsy to bipolar disorder
For maintenance treatment, a one-year open-label study of 56 bipolar patients found that adding topiramate to existing therapy was associated with fewer new manic and depressive episodes compared to the prior year.7PubMed. Adjunctive topiramate in the maintenance treatment of bipolar disorders: an open-label study These results are encouraging but carry serious caveats: none of these adjunctive trials were the kind of large, placebo-controlled, double-blind design that would generate a firm recommendation. The evidence is best described as suggestive. Topiramate appears to help some bipolar patients when added to their primary mood stabilizer, but it is not doing the heavy lifting on its own.
The Weight Loss Angle
One of the main reasons topiramate ends up in psychiatric treatment plans is weight. Many medications used for bipolar disorder and psychotic disorders cause significant weight gain, and topiramate is one of the few psychiatric-adjacent drugs that reliably causes weight loss. A randomized trial comparing topiramate to metformin for antipsychotic-induced obesity found that topiramate produced greater reductions in body weight and body mass index, with the differences becoming clear within the first month and continuing through 16 weeks.8PubMed Central. Outcomes and safety of concomitant topiramate or metformin for antipsychotics-induced obesity: a randomized-controlled trial
In adolescents with bipolar disorder who had gained weight on atypical antipsychotics or mood stabilizers, adding topiramate led to significant weight reduction. Interestingly, the same study also found reductions in mania scores, suggesting a possible dual benefit in this population.9PubMed. Topiramate in adolescents with juvenile bipolar disorder presenting weight gain due to atypical antipsychotics or mood stabilizers: an open clinical trial This dual action, managing weight while potentially nudging mood in the right direction, is a big part of why clinicians keep reaching for topiramate in bipolar treatment even though it is not a mood stabilizer in the formal sense.
Binge Eating and Impulsivity
Topiramate has shown genuinely strong effects on binge eating disorder, which often coexists with mood disorders. In a placebo-controlled trial of people with binge eating disorder and obesity, topiramate reduced binge frequency by about 94% compared to 46% for placebo. Participants who completed the study also lost an average of about 6 kilograms.10PubMed. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial A review of the available evidence on topiramate for binge eating noted that its combined ability to reduce impulsivity, stabilize mood, and promote weight loss makes it a particularly appealing option for this patient group.11PubMed Central. Treatment of obese patients with binge eating disorder using topiramate: a review
This matters for the mood stabilizer question because many people with bipolar disorder also struggle with binge eating and impulse control. Topiramate may be earning its place in treatment plans not by directly stabilizing mood but by addressing the impulsivity and disordered eating that complicate the picture. It is a tool with a different target than lithium or valproate, and understanding that distinction helps explain why it keeps getting prescribed in mood-disorder contexts without actually being a mood stabilizer.
Alcohol Dependence
Another off-label use that brings topiramate into the orbit of mood disorders is alcohol dependence. A randomized trial published in The Lancet found that people on topiramate drank roughly three fewer drinks per day compared to placebo, had about 28% fewer heavy drinking days, and were abstinent about 26% more of the time. Topiramate also reduced cravings significantly.12The Lancet. Topiramate for treating alcohol dependence: a randomised controlled trial A meta-analysis pooling results across multiple trials confirmed small to moderate benefits, with the strongest effects on abstinence and heavy drinking days.13PubMed Central. A meta-analysis of topiramate’s effects for individuals with alcohol use disorders
Alcohol misuse and bipolar disorder overlap heavily, so topiramate sometimes gets added to a bipolar regimen with the alcohol problem as the primary target. One study of alcohol-dependent patients found that those taking topiramate had significantly better mood outcomes, including improvements in both anxiety and depression, alongside longer periods of sobriety. The risk of relapse was roughly half that of the control group over the study period.14PubMed Central. Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study Again, these mood improvements are secondary to the primary goal of reducing drinking, but they contribute to the impression that topiramate “does something for mood,” which feeds the confusion about its classification.
Borderline Personality Disorder
Topiramate has also been tested in borderline personality disorder, a condition marked by intense mood swings, impulsivity, and interpersonal difficulties. A double-blind, placebo-controlled trial in women with BPD found that 10 weeks of topiramate treatment produced significant improvements in several symptom domains, including interpersonal sensitivity, anxiety, and hostility. It did not, however, improve depression or obsessive-compulsive symptoms in that trial.15PubMed. Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study The hostility and interpersonal sensitivity findings suggest topiramate may work on the impulsive-aggressive dimension of mood instability more than on sadness or elation per se.
Migraine and Mood Disorder Overlap
People with bipolar disorder have higher-than-average rates of migraine, and topiramate is one of the few drugs approved for migraine prevention. This overlap creates a practical situation where a single medication can address two problems at once. A review of treatment strategies for patients with both migraine and mood disorders noted that topiramate and valproate both have demonstrated efficacy in mood stabilization and are indicated for migraine without aura.16PubMed. Therapeutic strategies in migraine patients with mood and anxiety disorders: clinical evidence For a patient already taking a mood stabilizer who also needs migraine prevention, topiramate can be a logical add-on that serves double duty without actually replacing the mood stabilizer.
The Cognitive Side Effects Problem
If you have spent any time on patient forums, you have probably seen topiramate referred to by its unflattering nickname “Dopamax,” a reference to the brain fog and word-finding problems it can cause. This reputation is earned. Up to about 10% of patients report cognitive side effects, and the problems tend to show up within the first six weeks of treatment.17PubMed Central. Topiramate and cognitive impairment: evidence and clinical implications The most consistently documented issue is impaired verbal fluency, the ability to retrieve words and speak fluidly. Research has found a direct relationship between topiramate blood levels and the severity of problems with verbal fluency, word recall, and working memory speed.18PubMed Central. The effect of topiramate plasma concentration on linguistic behavior, verbal recall and working memory
The good news is that these problems are dose-dependent and often manageable. Starting at a low dose and increasing slowly, which clinicians call a slow titration, can reduce the likelihood and severity of cognitive complaints. Using topiramate at lower doses, as is typical for migraine prevention or as an adjunct in psychiatry, generally produces fewer cognitive effects than the higher doses sometimes used in epilepsy. Compared to other newer anticonvulsants like lamotrigine and levetiracetam, topiramate tends to fare worse on cognitive measures, particularly verbal fluency.17PubMed Central. Topiramate and cognitive impairment: evidence and clinical implications For patients who are already dealing with the cognitive effects of a mood disorder, adding a medication that dulls word retrieval is a real trade-off that needs to be weighed against whatever benefits topiramate brings.
Risks During Pregnancy
One of the most serious concerns with topiramate is its effect on fetal development. A large pregnancy cohort study found that the risk of oral clefts (cleft lip or palate) was roughly four times higher in infants exposed to topiramate during the first trimester compared to unexposed infants. The risk was especially pronounced at doses above 100 milligrams per day and in women with epilepsy, who tend to use higher doses.19PubMed Central. Topiramate use early in pregnancy and the risk of oral clefts: A pregnancy cohort study A separate large study examining 10 different antiepileptic drugs confirmed that topiramate was specifically associated with an increased risk of cleft lip.20PubMed Central. Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs A systematic review and meta-analysis put the overall odds ratio for oral clefts after first-trimester topiramate exposure at about 6.3, which represents strong evidence of a real risk.21PubMed. First trimester exposure to topiramate and the risk of oral clefts in the offspring: A systematic review and meta-analysis
This risk is relevant to the mood stabilizer question because many people with bipolar disorder are women of reproductive age who may become pregnant, sometimes unexpectedly. If topiramate were a primary mood stabilizer being relied on to prevent dangerous manic or depressive episodes, stopping it suddenly during pregnancy could have serious consequences. Its status as an add-on rather than a primary agent makes it somewhat easier to discontinue when pregnancy is planned, but it also means clinicians need to have this conversation proactively.
Interactions With Hormonal Contraception
Given the pregnancy risks, the interaction between topiramate and hormonal birth control deserves attention. The picture is more nuanced than early warnings suggested. At daily doses up to 200 milligrams, topiramate does not appear to reduce the effectiveness of combined oral contraceptives containing ethinyl estradiol and norethindrone.22PubMed. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects A large real-world study of migraine patients confirmed that low-dose topiramate combined with oral contraceptives did not produce a higher rate of unintended pregnancy compared to other migraine maintenance therapies.23PubMed. Real-world effect of a potential drug-drug interaction between topiramate and oral contraceptives on unintended pregnancy outcomes
The story is different for progestin-only methods. A study of women using the etonogestrel contraceptive implant found that as topiramate doses increased, blood levels of the contraceptive hormone dropped steadily. By the highest dose visit, over a third of participants had experienced a clinically meaningful decline.24PubMed Central. Effect of Topiramate on Serum Etonogestrel Concentrations Among Contraceptive Implant Users The practical takeaway: if you are using a progestin-only contraceptive and taking topiramate, discuss backup options with your prescriber, especially at higher doses. With combined oral pills at standard psychiatric doses, the interaction appears to be minimal.
Kidney Stones and Metabolic Acidosis
Topiramate’s inhibition of carbonic anhydrase does not just affect the brain. It changes the acid-base balance throughout the body, which can lead to metabolic acidosis, a condition where the blood becomes slightly too acidic. Over time, this can promote the formation of kidney stones, a well-recognized side effect. A case study documenting this process recommended that patients on long-term topiramate have their blood acid-base balance and urinary chemistry monitored, particularly if they develop kidney stones.25PubMed Central. Topiramate induced metabolic acidosis and kidney stones – a case study Staying well-hydrated and mentioning topiramate use to any doctor evaluating kidney symptoms are straightforward but often overlooked precautions. The risk is higher with prolonged use and higher doses, and people with a personal or family history of kidney stones should flag this before starting the medication.
When Topiramate Makes Sense in a Psychiatric Plan
Understanding what topiramate actually is, an anticonvulsant with useful psychiatric side benefits rather than a mood stabilizer, helps clarify when it earns a place in treatment. It tends to make the most sense as an add-on for people who are already on a primary mood stabilizer but dealing with secondary problems that topiramate happens to address well: medication-induced weight gain, binge eating, alcohol cravings, or comorbid migraines. In those scenarios, a single additional medication that tackles two or three issues at once is genuinely valuable, even if it is not doing the core mood-stabilizing work.
Where topiramate does not make sense is as a replacement for lithium, valproate, or lamotrigine. The four failed monotherapy mania trials are unambiguous on this point. If you are being told topiramate is your mood stabilizer, that is worth a conversation with your prescriber about what the primary agent in your regimen actually is. And if cognitive side effects or the pregnancy risk profile concerns you, those are legitimate reasons to explore alternatives for whatever secondary role topiramate is filling. There are other options for weight management, migraine prevention, and alcohol craving reduction that carry different trade-off profiles.